Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage
Status:
Withdrawn
Trial end date:
2027-01-18
Target enrollment:
Participant gender:
Summary
Brain bleed in premature infants damages the brain and survivors suffer from cerebral palsy
(weakness in the extremities), cognitive deficits, and neurobehavioral disorders. In this
clinical trial, investigators will test whether thyroxine (hormone from thyroid gland)
treatment in premature infants with moderate-to-large brain bleeds show recovery in the brain
structure on MRI evaluation at the time of discharge (44+/-1 weeks) and neurodevelopmental
improvement at 2 years of age.
Phase:
Phase 3
Details
Lead Sponsor:
Albert Einstein College of Medicine
Collaborators:
Arkansas Children's Hospital Research Institute Brigham and Women's Hospital Children's Minnesota Hospital Morgan Stanley Children's Hospital St. Louis University University of Minnesota University of North Carolina, Chapel Hill University of Pittsburgh Wake Forest University Health Sciences Westchester Medical Center